Drug Search Results
More Filters [+]

Defibrotide

Alternative Names: defibrotide, defibrotide sodium, Defiteli, defitelio
Latest Update: 2024-08-07
Latest Update Note: Clinical Trial Update

Product Description

Defibrotide is approved for the treatment of adult and pediatric patients with hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), with renal or pulmonary dysfunction following hematopoietic stem cell transplantation (HSCT). (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5135434/)

Mechanisms of Action: Unknown

Novel Mechanism: No

Modality: Peptide/Protein

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Approved

Approved Countries: Australia | Austria | Belgium | Brazil | Canada | Croatia | Czech | Denmark | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hungary | Iceland | Ireland | Israel | Italy | Japan | Korea | Latvia | Lithuania | Netherlands | Norway | Pakistan | Poland | Portugal | Romania | Saudi Arabia | Slovakia | Slovenia | Sweden | Switzerland | United Kingdom | United States

Approved Indications: None

Known Adverse Events: None

Company: Jazz
Company Location: DUBLIN L2 4
Company CEO: Bruce C. Cozadd
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Defibrotide

Countries in Clinic: United States

Active Clinical Trial Count: 2

Highest Development Phases

Phase 2: COVID-19

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2020P003203

P2

Recruiting

COVID-19

2024-09-01

DEFACOVID

P2

Active, not recruiting

COVID-19

2020-09-30

Recent News Events